Gilead's massive $7.8bn acquisition of Arcellx isn't just about pipeline depth; it’s a brutal market consolidation signal in the competitive **biotech M&A** landscape.
Madrigal's massive siRNA licensing deal signals a dangerous consolidation in the MASH drug race. The real winner isn't the patient.
Beneath the surface of Philadelphia's celebrated 2025 science breakthroughs lies a deeper, uncomfortable truth about funding and control in biotech.
Forget the hype. The real 2026 emerging technology shift isn't about shiny new gadgets, but a brutal capital reallocation.
The new supercomputer-modeled virtual brain isn't just science; it's the blueprint for future cognitive capture. Analyze the hidden costs.